96 related articles for article (PubMed ID: 23160010)
1. Studies on the mechanism of the DNA nicking property of amyloid-β40: implications in Alzheimer's disease.
Gupta VB; Monica FS; Berrocal R; Rao KS; Rao KS
J Alzheimers Dis; 2013; 33(4):1059-71. PubMed ID: 23160010
[TBL] [Abstract][Full Text] [Related]
2. A new evidence for DNA nicking property of amyloid beta-peptide (1-42): relevance to Alzheimer's disease.
Suram A; Hegde ML; Rao KS
Arch Biochem Biophys; 2007 Jul; 463(2):245-52. PubMed ID: 17502108
[TBL] [Abstract][Full Text] [Related]
3. A synthetic amino acid substitution of Tyr10 in Aβ peptide sequence yields a dominant negative variant in amyloidogenesis.
Mazargui H; Lévêque C; Bartnik D; Fantini J; Gouget T; Melone MA; Funke SA; Willbold D; Perrone L
Aging Cell; 2012 Jun; 11(3):530-41. PubMed ID: 22385841
[TBL] [Abstract][Full Text] [Related]
4. Alzheimer's disease and the amyloid β-protein.
Walsh DM; Teplow DB
Prog Mol Biol Transl Sci; 2012; 107():101-24. PubMed ID: 22482449
[TBL] [Abstract][Full Text] [Related]
5. Mass spectrometric characterization of amyloid-β species in the 7PA2 cell model of Alzheimer's disease.
Portelius E; Olsson M; Brinkmalm G; Rüetschi U; Mattsson N; Andreasson U; Gobom J; Brinkmalm A; Hölttä M; Blennow K; Zetterberg H
J Alzheimers Dis; 2013; 33(1):85-93. PubMed ID: 22886024
[TBL] [Abstract][Full Text] [Related]
6. Design and evaluation of a 6-mer amyloid-beta protein derived phage display library for molecular targeting of amyloid plaques in Alzheimer's disease: Comparison with two cyclic heptapeptides derived from a randomized phage display library.
Larbanoix L; Burtea C; Ansciaux E; Laurent S; Mahieu I; Vander Elst L; Muller RN
Peptides; 2011 Jun; 32(6):1232-43. PubMed ID: 21575663
[TBL] [Abstract][Full Text] [Related]
7. Application of yeast to study the tau and amyloid-β abnormalities of Alzheimer's disease.
Porzoor A; Macreadie IG
J Alzheimers Dis; 2013; 35(2):217-25. PubMed ID: 23396350
[TBL] [Abstract][Full Text] [Related]
8. A commonly used Drosophila model of Alzheimer's disease generates an aberrant species of amyloid-β with an additional N-terminal glutamine residue.
Allan K; Perez KA; Barnham KJ; Camakaris J; Burke R
FEBS Lett; 2014 Oct; 588(20):3739-43. PubMed ID: 25171862
[TBL] [Abstract][Full Text] [Related]
9. Dissecting the pathological effects of human Abeta40 and Abeta42 in Drosophila: a potential model for Alzheimer's disease.
Iijima K; Liu HP; Chiang AS; Hearn SA; Konsolaki M; Zhong Y
Proc Natl Acad Sci U S A; 2004 Apr; 101(17):6623-8. PubMed ID: 15069204
[TBL] [Abstract][Full Text] [Related]
10. Alzheimer's disease amyloid β-protein mutations and deletions that define neuronal binding/internalization as early stage nonfibrillar/fibrillar aggregates and late stage fibrils.
Poduslo JF; Howell KG; Olson NC; Ramirez-Alvarado M; Kandimalla KK
Biochemistry; 2012 May; 51(19):3993-4003. PubMed ID: 22545812
[TBL] [Abstract][Full Text] [Related]
11. Amyloid-beta peptide binds with heme to form a peroxidase: relationship to the cytopathologies of Alzheimer's disease.
Atamna H; Boyle K
Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3381-6. PubMed ID: 16492752
[TBL] [Abstract][Full Text] [Related]
12. First evidence for helical transitions in supercoiled DNA by amyloid Beta Peptide (1-42) and aluminum: a new insight in understanding Alzheimer's disease.
Hegde ML; Anitha S; Latha KS; Mustak MS; Stein R; Ravid R; Rao KS
J Mol Neurosci; 2004; 22(1-2):19-31. PubMed ID: 14742907
[TBL] [Abstract][Full Text] [Related]
13. Studies on the role of amino acid stereospecificity in amyloid beta aggregation.
Gupta VB; Indi SS; Rao KS
J Mol Neurosci; 2008; 34(1):35-43. PubMed ID: 18157656
[TBL] [Abstract][Full Text] [Related]
14. Low-n oligomers as therapeutic targets of Alzheimer's disease.
Ono K; Yamada M
J Neurochem; 2011 Apr; 117(1):19-28. PubMed ID: 21244429
[TBL] [Abstract][Full Text] [Related]
15. Heme-Cu bound aβ peptides: spectroscopic characterization, reactivity, and relevance to Alzheimer's disease.
Pramanik D; Ghosh C; Dey SG
J Am Chem Soc; 2011 Oct; 133(39):15545-52. PubMed ID: 21870836
[TBL] [Abstract][Full Text] [Related]
16. Modeling the binding mechanism of Alzheimer's Aβ1-42 to nicotinic acetylcholine receptors based on similarity with snake α-neurotoxins.
Maatuk N; Samson AO
Neurotoxicology; 2013 Jan; 34():236-42. PubMed ID: 23022323
[TBL] [Abstract][Full Text] [Related]
17. Single point mutations induce a switch in the molecular mechanism of the aggregation of the Alzheimer's disease associated Aβ42 peptide.
Bolognesi B; Cohen SI; Aran Terol P; Esbjörner EK; Giorgetti S; Mossuto MF; Natalello A; Brorsson AC; Knowles TP; Dobson CM; Luheshi LM
ACS Chem Biol; 2014 Feb; 9(2):378-82. PubMed ID: 24199868
[TBL] [Abstract][Full Text] [Related]
18. Generic hydrophobic residues are sufficient to promote aggregation of the Alzheimer's Abeta42 peptide.
Kim W; Hecht MH
Proc Natl Acad Sci U S A; 2006 Oct; 103(43):15824-9. PubMed ID: 17038501
[TBL] [Abstract][Full Text] [Related]
19. Active site environment of heme-bound amyloid β peptide associated with Alzheimer's disease.
Pramanik D; Dey SG
J Am Chem Soc; 2011 Jan; 133(1):81-7. PubMed ID: 21141958
[TBL] [Abstract][Full Text] [Related]
20. Development of retro-inverso peptides as anti-aggregation drugs for β-amyloid in Alzheimer's disease.
Matharu B; El-Agnaf O; Razvi A; Austen BM
Peptides; 2010 Oct; 31(10):1866-72. PubMed ID: 20633587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
